Several studies have demonstrated that treatment with 3-hydroxy-3-methylglutaryl coenzymes A reductase inhibitors (statins) can alter AAA vessel wall inflammation and reduce AAA expansion [28]–[30]. Here, HMGCR is linked to triple-A syndrome.